- Home
- SOAR vs XBIO Comparison
SOAR vs XBIO Comparison
Compare SOAR & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOAR | XBIO |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOAR | XBIO |
|---|---|---|
| Price | $0.56 | $2.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 28.6K |
| Earning Date | 11-13-2025 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | $0.35 | ★ N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.41 | $1.90 |
| 52 Week High | $6.48 | $13.93 |
Technical Indicators
Market Signals| Indicator | SOAR | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 57.08 |
| Support Level | $0.41 | $2.51 |
| Resistance Level | $0.73 | $2.79 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 39.57 | 65.44 |
Price Performance
Historical ComparisonAbout SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.